<SEC-DOCUMENT>0001104659-25-085705.txt : 20250829
<SEC-HEADER>0001104659-25-085705.hdr.sgml : 20250829
<ACCEPTANCE-DATETIME>20250829162113
ACCESSION NUMBER:		0001104659-25-085705
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250829
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Changes in Control of Registrant
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250829
DATE AS OF CHANGE:		20250829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Carisma Therapeutics Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		251281201

	BUSINESS ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104
		BUSINESS PHONE:		2674916422

	MAIL ADDRESS:	
		STREET 1:		3675 MARKET STREET
		STREET 2:		SUITE 401
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Sesen Bio, Inc.
		DATE OF NAME CHANGE:	20180516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2524685d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:CARM="http://carismatx.com/20250829">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_CARM_carismatx.com_20250829 -->
<!-- Field: Set; Name: xdx; ID: xdx_045_20250829_20250829 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0001485003 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000004" name="dei:EntityCentralIndexKey">0001485003</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="carm-20250829.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-08-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-08-29</xbrli:startDate>
        <xbrli:endDate>2025-08-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0pt">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt"></p>

<p style="margin: 0pt">&#160;</p>



<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_90C_edei--DocumentType_c20250829__20250829_zhsjzNHymDs8"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_900_edei--DocumentPeriodEndDate_c20250829__20250829_zxgck66dFeRc"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">August 29, 2025</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_902_edei--EntityRegistrantName_c20250829__20250829_zi6s9eaL0BI4"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000012" name="dei:EntityRegistrantName">Carisma Therapeutics Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact Name of Registrant as Specified in its
Charter)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20250829__20250829_zkasLR9QaFUd"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityFileNumber_c20250829__20250829_znENLf1kOqLi"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000014" name="dei:EntityFileNumber">001-36296</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt; width: 2%">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20250829__20250829_zJd3sUe76T1a"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000015" name="dei:EntityTaxIdentificationNumber">26-2025616</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b>(State or other jurisdiction<br/> of incorporation)</b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(Commission<br/> File Number)</b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top"><b>(IRS Employer<br/> Identification No.)</b></td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="text-align: center; vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="text-align: center; vertical-align: top"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250829__20250829_zb3GKE0SLvqb"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000016" name="dei:EntityAddressAddressLine1">3675 Market Street</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressAddressLine2_c20250829__20250829_zdbhFkUj9ejg"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000017" name="dei:EntityAddressAddressLine2">Suite&#160;401</ix:nonNumeric></span><br/> <span id="xdx_906_edei--EntityAddressCityOrTown_c20250829__20250829_zauWSi3jXM64"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000018" name="dei:EntityAddressCityOrTown">Philadelphia</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20250829__20250829_z3NkM4OYPKTh"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000019" name="dei:EntityAddressStateOrProvince">PA</ix:nonNumeric> </span></b></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20250829__20250829_z5BAVdLIN7Oi"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000020" name="dei:EntityAddressPostalZipCode">19104</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address of Principal Executive Offices)</b></span></td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center">&#160;</td>
    <td style="text-align: center; vertical-align: bottom; font-size: 10pt">&#160;</td>
    <td style="vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>( Zip Code)</b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including
area code: (<span id="xdx_906_edei--CityAreaCode_c20250829__20250829_zxCwnulWYtD5"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000021" name="dei:CityAreaCode">267</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20250829__20250829_ziXslilSObF1"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000022" name="dei:LocalPhoneNumber">491-6422</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed
Since Last Report)</b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see </i>General Instruction
A.2 below):<span style="font-family: Wingdings"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90D_edei--WrittenCommunications_c20250829__20250829_zj3xKVxj3S4a"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt:booleantrue" id="Fact000023" name="dei:WrittenCommunications">x</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_901_edei--SolicitingMaterial_c20250829__20250829_ziA7NTOkcUFi"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt:booleanfalse" id="Fact000024" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_909_edei--PreCommencementTenderOffer_c20250829__20250829_z0cxpqZXx3k6"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20250829__20250829_zShOsQtjuSr9"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt:booleanfalse" id="Fact000026" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="width: 45%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 24%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 29%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading<br/> Symbol(s)</b></span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center"><b>Name of exchange<br/> on which registered</b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--Security12bTitle_c20250829__20250829_zmd0AlkboZmf"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000027" name="dei:Security12bTitle">Common
    Stock, $0.001 par value per share</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--TradingSymbol_c20250829__20250829_zTzAIl1iBG13"><ix:nonNumeric contextRef="AsOf2025-08-29" id="Fact000028" name="dei:TradingSymbol">CARM</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--SecurityExchangeName_c20250829__20250829_zNqquHZ33rGa"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></b></span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Emerging growth company&#160;</span><span style="font-family: Wingdings"><span id="xdx_902_edei--EntityEmergingGrowthCompany_c20250829__20250829_zissL4fgQkdl"><ix:nonNumeric contextRef="AsOf2025-08-29" format="ixt:booleanfalse" id="Fact000030" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>Item</b> <b>1.01. Entry into a Material Definitive Agreement.</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Background</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As previously disclosed, Carisma Therapeutics
Inc. (the &#8220;Company&#8221;) entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated as of June&#160;22,
2025, by and among the Company, Azalea Merger Sub,&#160;Inc., a Delaware corporation and a wholly owned subsidiary of the Company (&#8220;Merger
Sub&#8221;), Ocugen,&#160;Inc., a Delaware corporation (&#8220;Ocugen&#8221;), and OrthoCellix,&#160;Inc. (&#8220;OrthoCellix&#8221;),
a Delaware corporation and wholly-owned subsidiary of Ocugen, pursuant to which, among other matters, and subject to the satisfaction
or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into OrthoCellix (the &#8220;Merger&#8221;),
with OrthoCellix continuing as a wholly owned subsidiary of the Company and the surviving company of the Merger. Pursuant to the Merger
Agreement, the Company and OrthoCellix have agreed to use commercially reasonable efforts to enter into subscription agreements with one
or more investors designated by OrthoCellix (the &#8220;Investors&#8221;), pursuant to which such anticipated Investors would agree to
purchase, at or immediately following the closing of the Merger, shares of common stock, par value $0.001 per share, of the Company (&#8220;Common
Stock&#8221;) for aggregate gross proceeds at least equal to $25.0 million (the &#8220;Concurrent Investment&#8221;). Pursuant to the
Merger Agreement, Ocugen agreed to enter into a subscription agreement with the Company, pursuant to which Ocugen will commit to purchase,
as part of the anticipated Concurrent Investment, shares of Common Stock for aggregate gross proceeds equal to not less than $5.0 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Subscription Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">On
August 29, 2025, as part of the anticipated Concurrent Investment, the Company entered into a subscription agreement with Ocugen (the
&#8220;Subscription Agreement&#8221;), pursuant to which the Company agreed to issue and sell to Ocugen in a private placement (the &#8220;Ocugen
Investment&#8221;) an aggregate of $5.0 million of shares of Common Stock (the &#8220;Ocugen Shares&#8221;), which is expected to be at
a price per share</span> to be calculated by dividing (i) the Aggregate Valuation (as defined in the Merger Agreement) by (ii) the Post-Closing
Parent Shares (as defined in the Merger Agreement).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Subscription Agreement, if the
Company grants to any anticipated Investors in the anticipated Concurrent Investment any rights, privileges or protections more favorable
than those granted to Ocugen under the Subscription Agreement or the Registration Rights Agreement (as defined below), then Ocugen shall
be automatically entitled to such more favorable rights, privileges and protections, subject to certain specified exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Ocugen Investment is expected to be consummated
as part of the anticipated Concurrent Investment at or immediately following the closing of the Merger, subject to approval by the Company&#8217;s
stockholders under the rules of The Nasdaq Stock Market LLC of the issuance of shares of Common Stock in the Merger and in the anticipated
Concurrent Investment, the closing of the Merger and the satisfaction of other customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chardan Capital Markets LLC and Lake Street Capital
Markets, LLC are acting as placement agents for the Ocugen Investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company also intends to enter into a registration
rights agreement (the &#8220;Registration Rights Agreement&#8221;) with the Investors that participate in the anticipated Concurrent Investment,
including Ocugen, at the closing of the anticipated Concurrent Investment, pursuant to which, among other things, the Company will agree
to provide for the registration of the resale of certain shares of Common Stock that are held by such Investors, including the Ocugen
Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preceding summary of the Subscription Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Subscription Agreement, a copy of
which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ending September 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02. Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in Item 1.01 of this
Current Report on Form 8-K is incorporated herein by reference. Based in part upon the representations of Ocugen in the Subscription Agreement,
the offering and sale of the Ocugen Shares will be exempt from registration under Section 4(a)(2) of the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;). The Ocugen Shares have not been registered under the Securities Act or any state securities laws,
and the Ocugen Shares may not be offered or sold in the United States absent registration with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) or an applicable exemption from the registration requirements. The sale of the Ocugen Shares will not involve
a public offering and will be made without general solicitation or general advertising. Ocugen represented that it is an institutional
&#8220;accredited investor&#8221; as defined in Rule 501(a) under Regulation D promulgated pursuant to the Securities Act or a &#8220;qualified
institutional buyer&#8221; within the meaning of Rule 144A under the Securities Act, and that Ocugen is acquiring the Ocugen Shares for
investment purposes only and not with a view to any resale, distribution or other disposition of the Ocugen Shares in violation of the
United States federal securities laws.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><b>Item 5.01.&#160;<span style="background-color: white">Changes
in Control of Registrant</span>.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">To the extent required by
this Item, the information contained in Item 1.01 of this Current Report on Form&#160;8-K&#160;is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Amended and Restated Employment Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August&#160;29, 2025, at the request of OrthoCellix,
the Company entered into an Amended and Restated Employment Agreement with Steven Kelly, the Company&#8217;s President and Chief Executive
Officer (the &#8220;A&amp;R Employment Agreement&#8221;), which amends and restates Mr.&#160;Kelly&#8217;s Employment Agreement, dated
March&#160;7, 2023, with the Company (the &#8220;Original Employment Agreement&#8221;), subject to and effective upon the closing of the
Merger. Pursuant to the A&amp;R Employment Agreement, Mr.&#160;Kelly will serve as the Company&#8217;s President and Chief Executive Officer
following the Merger. The A&amp;R Employment Agreement provides for substantially similar compensation arrangements as the Original Employment
Agreement, except that the A&amp;R Employment Agreement (i)&#160;reflects Mr.&#160;Kelly&#8217;s current base salary that was implemented
as part of the Company&#8217;s annual compensation review in December&#160;2024, (ii)&#160;clarifies that the Merger will not constitute
a &#8220;Change in Control&#8221; under the A&amp;R Employment Agreement and (iii)&#160;provides that the Company will grant Mr.&#160;Kelly,
on or following the closing of the Merger, an option for a number of shares of the Company&#8217;s common stock equal to 4.0% of the fully
diluted capitalization of the Company at the closing of the Merger, which option will have an exercise price equal to the closing price
of the Company&#8217;s common stock on the grant date and will vest in three equal annual installments beginning on the first anniversary
of the grant date and ending on the third anniversary of the grant date, subject to Mr.&#160;Kelly&#8217;s continued service through the
applicable vesting dates. In the event the Merger does not close, the A&amp;R Employment Agreement will be void and of no force or effect
and the Original Employment Agreement will remain in effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Retention and Transaction Bonus Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, on August&#160;29, 2025, the Company
entered into a Retention and Transaction Bonus Agreement with Mr.&#160;Kelly (the &#8220;Bonus Agreement&#8221;). Pursuant to the Bonus
Agreement, if Mr.&#160;Kelly remains continuously employed by the Company through the earlier of (i)&#160;the date of the closing of the
Merger and (ii)&#160;October&#160;31, 2025 (such earliest date, the &#8220;Retention Date&#8221;), subject to his execution and non-revocation
of a release of claims in favor of the Company, Mr.&#160;Kelly will be entitled to receive a retention bonus in a lump sum amount equal
to the sum of (i)&#160;12 months of his current base salary and (ii)&#160;100.0% of his 2025 annual discretionary bonus at target, prorated
based on the Retention Date (the &#8220;Retention Bonus&#8221;). If Mr.&#160;Kelly becomes eligible for the Retention Bonus on October&#160;31,
2025 (because Mr.&#160;Kelly remained continually employed by the Company through October&#160;31, 2025 and the closing of the Merger
has not occurred by that date), as a condition of receiving the Retention Bonus, Mr.&#160;Kelly must forgo the severance benefits set
forth in his Original Employment Agreement, other than certain continued healthcare benefits payments pursuant to the terms and conditions
of the Original Employment Agreement. In addition, pursuant to the Bonus Agreement, if the closing of the Merger occurs prior to October&#160;31,
2025, contingent upon Mr.&#160;Kelly remaining continuously employed by the Company through such closing of the Merger and subject to
his execution and non-revocation of a release of claims in favor of the Company, Mr.&#160;Kelly will be entitled to an additional transaction
bonus in a lump sum amount equal to the difference of (i)&#160;the sum of (x)&#160;18 months of his current base salary, (y)&#160;150.0%
of his 2025 annual discretionary bonus at target, and (z)&#160;100.0% of his 2025 annual discretionary bonus at target, prorated based
on the date of the closing of the Merger, minus (ii)&#160;the Retention Bonus (the &#8220;Transaction Bonus&#8221;, and together with
the Retention Bonus, the &#8220;Bonuses&#8221;). If Mr.&#160;Kelly&#8217;s employment with the Company is terminated for any reason prior
to the Retention Date, Mr.&#160;Kelly will not be eligible to receive the Bonuses pursuant to the Bonus Agreement and will remain eligible
to receive any applicable severance benefits set forth in the Original Employment Agreement, pursuant to the terms and conditions of the
Original Employment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing descriptions of the A&amp;R Employment
Agreement and the Bonus Agreement do not purport to be complete and are qualified in their entirety by reference to the complete text
of such agreements, copies of which are attached as Exhibit&#160;10.1 and Exhibit&#160;10.2 hereto, respectively, and incorporated by
reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><b>Item 8.01. Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="background-color: white">As previously
disclosed, by a decision dated June&#160;10, 2025 (the &#8220;Panel Decision&#8221;), the Nasdaq Hearings Panel (the &#8220;Panel&#8221;)
granted the Company&#8217;s request for the transfer of its listing to The Nasdaq Capital Market (&#8220;NCM&#8221;), pursuant to an exception,
ultimately through October&#160;7, 2025, to evidence compliance with all applicable criteria for listing on the NCM, including the applicable
bid price requirement (the &#8220;NCM Bid Price Rule&#8221;) and complete a strategic transaction. Nasdaq transferred the Company&#8217;s
listing to the NCM effective as of the open of business on June&#160;12, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">In early August&#160;2025, the
Company sent a written update and request to the Panel seeking to modify certain terms of the Panel Decision. The Panel subsequently notified
the Company that, based on the Company&#8217;s satisfaction of the milestones thus far set forth in the Panel Decision </span>and the
Company&#8217;s progress toward completing the Merger and reverse stock split within the timeframes presented to the Panel, <span style="background-color: white">the
Panel granted the Company&#8217;s request to modify the Panel Decision to provide that the Company must demonstrate continued compliance
with the NCM Bid Price Rule&#160;by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading
sessions on or before October&#160;21, 2025, instead of on or before October&#160;7, 2025. The other terms of the Panel Decision for continued
listing on the NCM remained the same, which are that: (i)&#160;on or before October&#160;7, 2025, the Company must complete the Merger
and (ii)&#160;on or before October&#160;7, 2025, the Company must demonstrate compliance with all initial listing requirements for the
NCM, including a closing bid price of $4.00 or more per share prior to the closing of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">The Panel has the right to reconsider
its determination based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make
continued listing of the Company&#8217;s securities inadvisable or unwarranted. There can be no assurance that the Company will be able
to satisfy the requirements or conditions for continued listing within the period of time granted by the Panel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529"><b>Item 9.01&#160;Financial
Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; color: #212529">(d)&#160;Exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2524685d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2524685d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated
    Employment Agreement, dated August&#160;29, 2025, by and between the Company and Steven Kelly</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2524685d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2524685d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retention and Transaction Bonus Agreement, dated August&#160;29,
    2025, by and between the Company and Steven Kelly</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File (embedded within
    the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Cautionary Note on Forward-Looking Statements</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Current Report on Form&#160;8-K contains
forward-looking statements that involve substantial risks and uncertainties, including statements regarding the anticipated closing of
the Ocugen Investment and the anticipated Concurrent Investment; whether the conditions for the closing of the Concurrent Investment will
be satisfied, including the closing of the Merger; the anticipated proceeds from the Ocugen Investment and the anticipated Concurrent
Investment; and the filing of a registration statement to register the resale of the Ocugen Shares and anticipated Bonuses in connection
with the Merger. All statements, other than statements of historical facts, contained in this Current Report on Form&#160;8-K, including
statements regarding the Company&#8217;s strategy, future operations, prospects, plans and objectives of management, are forward-looking
statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221;
&#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
&#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue,&#8221; and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions
or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements
the Company makes as a result of various risks and uncertainties include, but are not limited to, the risk that the conditions to the
closing of the proposed Merger (the &#8220;Closing&#8221;) or consummation of the proposed Concurrent Investment and the Merger (the &#8220;Proposed
Transactions&#8221;) are not satisfied, including the failure to timely obtain approval of the proposed Merger from both the Company&#8217;s
and OrthoCellix&#8217;s stockholders; the risk that the proposed Concurrent Investment is not completed in a timely manner, if at all;
uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of each of the Company and OrthoCellix
to consummate the Proposed Transactions; risks related to the Company&#8217;s continued listing on Nasdaq until closing of the Proposed
Transactions and the combined company&#8217;s ability to remain listed following the Closing; risks related to the Company&#8217;s and
OrthoCellix&#8217;s ability to correctly estimate their respective operating expenses and their respective expenses associated with the
Proposed Transactions, as applicable, pending the Closing, as well as uncertainties regarding the impact any delay in the Closing would
have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce
the combined company&#8217;s cash resources; risks related to the failure or delay in obtaining required approvals from any governmental
or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence of any event, change or other circumstance
or condition that could give rise to the termination of the Merger Agreement; the effect of the announcement or pendency of the Merger
on the Company&#8217;s or OrthoCellix&#8217;s business relationships, operating results and business generally; costs related to the Merger;
the risk that as a result of adjustments to the exchange ratio, OrthoCellix&#8217;s stockholders and the Company&#8217;s stockholders
could own more or less of the combined company than is currently anticipated; risks related to the market price of the Common Stock relative
to the value suggested by the exchange ratio; the uncertainties associated with OrthoCellix&#8217;s NeoCart&#174; portfolio, as well as
risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion
of clinical trials; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance
these product candidates; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may
result therefrom; risks related to the failure to realize any value from product candidates being developed and anticipated to be developed
in light of inherent risks and difficulties involved in successfully bringing product candidates to market; the outcome of any legal proceedings
that may be instituted against the Company, OrthoCellix or any of their respective directors or officers related to the Proposed Transactions;
the ability of the Company and OrthoCellix to obtain, maintain, and protect their respective intellectual property rights; competitive
responses to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges or expenses resulting from the
Proposed Transactions; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting
from the announcement or completion of the Proposed Transactions; changes in regulatory requirements and government incentives; risks
associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of
the Proposed Transactions, including with respect to future financial and operating results, legislative, regulatory, political and economic
developments, and those uncertainties and factors; and the risk of involvement in litigation, including securities class action litigation,
that could divert the attention of the management of the Company or the combined company, harm the combined company&#8217;s business and
may not be sufficient for insurance coverage to cover all costs and damages, among others. Actual results and the timing of events could
differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other
risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled
&#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, which was
originally filed with the SEC on March&#160;31, 2025, as amended by Amendment No.&#160;1 to the Annual Report on Form&#160;10-K/A, which
was filed with the SEC on April&#160;29, 2025, subsequent Quarterly Reports on Form&#160;10-Q filed with the SEC, and in other filings
that the Company makes and will make with the SEC in connection with the Proposed Transactions, including the Form&#160;S-4 and Proxy
Statement described below under &#8220;Important Additional Information and Where to Find It&#8221;, as well as discussions of potential
risks, uncertainties, and other important factors included in other filings by the Company from time to time, any risk factors related
to the Company or OrthoCellix made available to you in connection with the Proposed Transactions, as well as risk factors associated with
companies, such as OrthoCellix, that operate in the biopharma industry. Should one or more of these risks or uncertainties materialize,
or should any of the Company&#8217;s or OrthoCellix&#8217;s assumptions prove incorrect, actual results may vary in material respects
from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any
person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only
as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither the Company
nor OrthoCellix undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any
such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and
other attributes of an investment in the Company or OrthoCellix.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">No Offer or Solicitation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication and the information contained
herein is not intended to and does not constitute (i)&#160;a solicitation of a proxy, consent or approval with respect to any securities
or in respect of the proposed Merger or otherwise or (ii)&#160;an offer to sell or the solicitation of an offer to subscribe for or buy
or an invitation to purchase or subscribe for any securities pursuant to the proposed Merger or otherwise, nor shall there be any sale,
issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except
by means of a prospectus meeting the requirements of Section&#160;10 of the&#160;Securities Act of 1933, as amended, and otherwise in
accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or
certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so
would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without
limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities
exchange, of any such jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION
HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Important Additional Information and Where
to Find It</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This communication relates to the proposed Merger
involving the Company and OrthoCellix and may be deemed to be solicitation material in respect of the proposed Merger or otherwise. In
connection with the proposed Merger, the Company has filed relevant materials with the SEC, including a registration statement on Form&#160;S-4
(the &#8220;Form&#160;S-4&#8221;) which contains a proxy statement (the &#8220;Proxy Statement&#8221;) and prospectus. This communication
is not a substitute for the Form&#160;S-4, the Proxy Statement or for any other document that the Company may file with the SEC and/or
send to the Company&#8217;s stockholders in connection with the proposed Merger. THE COMPANY URGES, BEFORE MAKING ANY VOTING DECISION
FOR THE MERGER,&#160;INVESTORS AND STOCKHOLDERS TO READ THE FORM&#160;S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY&#160;BE
FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME
AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, ORTHOCELLIX, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investors and stockholders will be able to obtain
free copies of the Form&#160;S-4, the Proxy Statement and other documents filed by the Company with the SEC (when they become available)
through the website maintained by the SEC at&#160;<i>www.sec.gov</i>. Copies of the documents filed by the Company with the SEC will also
be available free of charge on the Company&#8217;s website at&#160;<i>www.carismatx.com</i>, or by contacting the Company&#8217;s Investor
Relations at investors@Carismatx.com. In addition, investors and stockholders should note that the Company communicates with investors
and the public using its website at https://ir.Carismatx.com/.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration: underline">Participants in the Solicitation</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company, OrthoCellix, and their respective
directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation
of proxies from the Company&#8217;s stockholders in connection with the proposed Merger and the related matters under the rules&#160;of
the SEC. Information about the Company&#8217;s directors and executive officers, including a description of their interests in the Company,
is included in the Company&#8217;s most recent Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, which was filed
with the SEC on March&#160;31, 2025, as amended by Amendment No.&#160;1 to the Annual Report on Form&#160;10-K, which was filed with the
SEC on April&#160;29, 2025. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including
information about the directors and executive officers of OrthoCellix, and a description of their direct and indirect interests, by security
holdings or otherwise, have been included, as applicable, in the Form&#160;S-4, the Proxy Statement and other relevant materials to be
filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 6 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="font-size: 10pt"><span style="font-size: 10pt"><b>CARISMA THERAPEUTICS INC.</b></span></td></tr>
  <tr>
    <td style="vertical-align: top; width: 50%">&#160;</td>
    <td style="vertical-align: top; width: 3%">&#160;</td>
    <td style="vertical-align: bottom; width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font-size: 10pt"><span style="font-size: 10pt">/s/ Steven Kelly</span></td></tr>
  <tr>
    <td style="vertical-align: top; font-size: 10pt"><span style="font-size: 10pt">Date: August 29, 2025</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt">Steven Kelly</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; font-size: 10pt"><span style="font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5LhpDBe2jRYtYRYqIr8FuJdhmyyb+HclbGlvEZWFZZr4ZIWKR08o0yHBalAUcsO0a7RFKrJHRnjE4svUmhXBLvBjnWVvfvz8wo8BgYKYjpXQQeuvdOKxSkMlYzscqATlLpwnstyL66hnZ2lRovdENaFvBnqljg17za0g46CdZal991RHZGbIpTEZykN+g5ETBju76QXx1UBSZiOJ+IpEz3brgWj492i8JywbbUOcG+r/RBwwoSpY= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2524685d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: #231f20"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>EMPLOYMENT AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS AMENDED AND RESTATED
EMPLOYMENT AGREEMENT (the &ldquo;Agreement&rdquo;), is made as of August 29, 2025 and amends and restates the Employment Agreement (the
 &ldquo;Prior Agreement&rdquo;) dated March&nbsp;7, 2023, by and between Carisma Therapeutics Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
and Steven Kelly (the &ldquo;Executive&rdquo;) (together, the &ldquo;Parties&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20">RECITALS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive has
been employed by the Company pursuant to the Prior Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, pursuant to that
certain Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;), dated June&nbsp;22, 2025, among the Company, Azalea Merger
Sub,&nbsp;Inc., a Delaware corporation and wholly owned subsidiary of the Company (&ldquo;Merger Sub&rdquo;), Ocugen,&nbsp;Inc. (&ldquo;Ocugen&rdquo;),
a Delaware corporation, and OrthoCellix,&nbsp;Inc. (&ldquo;OrthoCellix&rdquo;), a Delaware corporation and wholly-owned subsidiary of
Ocugen, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into
OrthoCellix (the &ldquo;Merger&rdquo;), with OrthoCellix continuing as a wholly owned subsidiary of the Company and the surviving company
of the Merger;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, upon closing of the
Merger, the Company will change its name to &ldquo;OrthoCellix,&nbsp;Inc.&rdquo;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Parties desire
to amend and restate the Prior Agreement as set forth in this Agreement, which is contingent upon and will be effective upon closing of
the Merger (the &ldquo;Effective Date&rdquo;), whereby the Executive will be employed as President and Chief Executive Officer of the
Company on the terms contained in this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Executive has
agreed to accept such continued employment with the Company following the Merger on the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the foregoing and of the respective covenants and agreements of the Parties herein contained, the Parties hereto agree to the following
terms, which shall govern the Executive&rsquo;s employment from and after the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1. <I>Agreement</I>. This Agreement shall be effective
as of the Effective Date. If there is no closing of the Merger, this Agreement shall be void and of no force or effect, and the Prior
Agreement shall remain in full force and effect. The Executive&rsquo;s employment on the terms contained in this Agreement shall commence
on the Effective Date and shall continue until such employment relationship is terminated in accordance with Section&nbsp;7 hereof (the
 &ldquo;Term of Employment&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2. <I>Position</I>. During the Term of Employment,
the Executive shall serve as the President and Chief Executive Officer of the Company and shall serve on the Company&rsquo;s board of
directors (the &ldquo;Board&rdquo;), subject to his reelection thereto from time to time by the Company&rsquo;s stockholders, working
out of the Company&rsquo;s office in Pennsylvania, and travelling as reasonably required by the Executive&rsquo;s job duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3. <I>Scope of Employment</I>. During the Term
of Employment, the Executive shall be responsible for the performance of those duties consistent with the Executive&rsquo;s position as
President and Chief Executive Officer. The Executive shall report to the Board. The Executive agrees to devote the Executive&rsquo;s full
business time, best efforts, skill, knowledge, attention, and energies to the advancement of the Company&rsquo;s business and interests
and to the performance of the Executive&rsquo;s duties and responsibilities as an employee of the Company and not to engage in any other
business activities (whether as an employee, consultant, board member, advisor or in any other capacity) without prior approval from the
Company, except (a)&nbsp;as set forth on <U>Schedule 1</U> attached hereto and (b)&nbsp;the Executive may engage in charitable or civic
activities and/or serve as an executor, trustee, or other similar fiduciary capacity, provided, however, that in no event may any activity
be undertaken or continued if it would (i)&nbsp;be in violation of any provision of this Agreement or other agreement between the Executive
and the Company, (ii)&nbsp;interfere with the performance of the Executive&rsquo;s duties for the Company, or (iii)&nbsp;present a conflict
of interest with the Company&rsquo;s business interests. As an employee of the Company, the Executive will be required to comply with
all Company policies and procedures. Violations of the Company&rsquo;s policies may lead to immediate termination of the Executive&rsquo;s
employment, provided, however, that nothing in the foregoing shall alter any rights the Executive may have as set forth in Section&nbsp;8
below. Further, the Company&rsquo;s premises, including all workspaces, furniture, documents, and other tangible materials, and all information
technology resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to
oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with regard to any Company
premises, materials, resources, or information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4. <I>Compensation</I>. As full compensation for
all services rendered by the Executive to the Company and any affiliate thereof, during the Term of Employment, the Company will provide
to the Executive the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>Base Salary</I>.
During the Term of Employment, the Executive shall receive a base salary, effective as of the Effective Date, at the annualized rate of
$624,000 (the &ldquo;Base Salary&rdquo;). The Executive&rsquo;s Base Salary shall be paid in equal installments in accordance with the
Company&rsquo;s regularly established payroll procedures. The Executive&rsquo;s Base Salary will be reviewed on an annual or more frequent
basis by the Board and is subject to change in the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<I>Annual Discretionary
Bonus</I>. During the Term of Employment, the Executive will be eligible to receive an annual discretionary performance bonus with a target
amount equal to 55% of the Executive&rsquo;s Base Salary (the &ldquo;Target Bonus&rdquo;). The amount of any bonus, if any, shall be determined
by the Board in its sole discretion, based on the Board&rsquo;s assessment of the Executive&rsquo;s performance and the Company&rsquo;s
attainment of targeted goals to be set by the Board in its sole discretion. Following the close of each calendar year, the Board will
determine whether the Executive has earned a performance bonus, and the amount of any performance bonus, based on the set criteria. No
amount of the performance bonus is guaranteed, and the Executive must be an active employee of the Company on the date the bonus is distributed
in order to be eligible for and to earn any bonus award, as it also serves as an incentive for the Executive to remain employed by the
Company. The Executive&rsquo;s Target Bonus eligibility will be reviewed on an annual or more frequent basis by the Board and is subject
to change in the discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<I>Equity Award.
</I>On or as soon as practicable following the Effective Date (the &ldquo;Grant Date&rdquo;), subject to the approval of the Board of
Directors of the Company, the Company will grant the Executive a stock option (the &ldquo;Initial Award&rdquo;) to purchase a number of
shares equal to 4.0% of the Fully Diluted Shares (as defined below) of the Company as of the closing of the Merger. The exercise price
per share will be equal to the closing price of the Company&rsquo;s common stock on the Nasdaq Stock Market on the Grant Date. The Initial
Award will vest in three equal annual installments beginning on the first anniversary of the Grant Date and ending on the third anniversary
of the Grant Date, subject in each case to the Executive&rsquo;s continued service to the Company through the applicable vesting date.
The Initial Award is expected to be granted pursuant to the OrthoCellix,&nbsp;Inc. 2025 Stock Option and Incentive Plan and will be an
incentive stock option to the maximum extent permitted by applicable federal tax laws. Other than the Initial Award, the Executive will
be eligible to receive additional equity awards, if any, at such times and on such terms and conditions as the Board shall, in its sole
discretion, determine. &ldquo;Fully Diluted Shares&rdquo; shall mean the outstanding shares of the Company (assuming conversion or exercise
of all then-outstanding convertible securities and any unissued pool under the Company&rsquo;s equity incentive plans).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<FONT STYLE="color: #231f20"><I>Paid
Time Off</I>. The Executive will be eligible for a maximum of twenty-five (25) days of paid time off (&ldquo;PTO&rdquo;) per calendar
year to be taken at such times as may be approved by the Company. The number of PTO days for which the Executive is eligible shall accrue
at the rate of 2.083 days per month that the Executive is employed during such calendar year. Any unused PTO time will be forfeited at
the end of each calendar year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<FONT STYLE="color: #231f20"><I>Benefits</I>.
Subject to eligibility requirements and the Company&rsquo;s polices, the Executive shall have the right, on the same basis as other similarly-situated
employees of the Company, to participate in, and to receive benefits under, all employee health, disability, insurance, fringe, welfare
benefit and retirement plans, arrangements, practices and programs the Company provides to its senior executives in accordance with the
terms thereof as in effect from time to time. The Company reserves the right to modify, amend and/or terminate any and all of its benefits
plans at is discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<FONT STYLE="color: #231f20"><I>Withholdings</I>.
All compensation payable to the Executive shall be subject to applicable taxes and withholdings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5. <I>Expenses</I>. The Executive will be reimbursed
for the Executive&rsquo;s actual, necessary and reasonable business expenses pursuant to Company policy, subject to the provisions of
Section&nbsp;3 of <U>Exhibit&nbsp;A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6. <I>Restrictive Covenants Agreements</I>. The
Executive hereby acknowledges that each of the Invention and Non-Disclosure Agreement and the Non-Competition and Non-Solicitation Agreement
that the Executive previously executed in connection with the Executive&rsquo;s employment with CTx Operations,&nbsp;Inc. (together, the
 &ldquo;Restrictive Covenant Agreements&rdquo;) remain in full force and effect, with the terms thereof hereby deemed incorporated herein;
provided, however, that the references therein to &ldquo;Company&rdquo; shall be deemed hereinafter to mean the Company, as well as the
Carisma Sub. The Executive further acknowledges that the Executive&rsquo;s employment with the Company is conditioned on the Executive&rsquo;s
continued compliance with the Restrictive Covenant Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7. <I>Employment Termination</I>. This Agreement
and the employment of the Executive shall terminate upon the occurrence of any of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;Upon the death of
the Executive or at the election of the Company due to the Executive&rsquo;s &ldquo;Disability&rdquo;. As used in this Agreement, the
term &ldquo;Disability&rdquo; shall mean a physical or mental illness or disability that prevents the Executive from performing the duties
of the Executive&rsquo;s position for a period of more than any three (3)&nbsp;consecutive months or for periods aggregating more than
twenty-six (26) weeks. The Company shall determine in good faith and in its sole discretion whether the Executive is unable to perform
the services provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;At the election of
the Company, with or without &ldquo;Cause&rdquo; (as defined below), immediately upon written notice by the Company to the Executive.
As used in this Agreement, &ldquo;Cause&rdquo; shall mean:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Executive&rsquo;s engagement in any conduct that has materially and adversely affected, or is reasonably likely to materially and adversely
affect, the business interests or reputation of the Company (for avoidance of doubt, &ldquo;conduct&rdquo; in this subsection does not
mean poor performance or failure to meet Company objectives);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>any
breach by the Executive of the Restrictive Covenant Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Executive&rsquo;s willful and repeated failure to perform in any material respect, the Executive&rsquo;s duties to the Company under
this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Executive&rsquo;s fraud or embezzlement, or the Executive&rsquo;s willful misconduct with respect to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Executive&rsquo;s material breach of this Agreement; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
Executive&rsquo;s conviction of, or plea of guilty or <I>nolo contendere</I> to, a misdemeanor relating to the Company, any crime involving
dishonesty or moral turpitude, or any felony;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">provided however, that with respect to subsections
(i), (ii)&nbsp;(iii)&nbsp;and (v)&nbsp;hereof, the Executive was given thirty (30) calendar days&rsquo; written notice of such conduct,
breach, or deficiencies and an opportunity to cure such conduct, breach or deficiencies but the Executive failed to do so within such
period (provided that the Executive is eligible for no more than two &ldquo;cure&rdquo; opportunities during the Executive&rsquo;s employment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;At the election of
the Executive, with or without &ldquo;Good Reason&rdquo; (as defined below), upon written notice by the Executive to the Company (subject,
if it is with Good Reason, to the timing provisions set forth in the definition of Good Reason). As used in this Agreement, &ldquo;Good
Reason&rdquo; shall mean the occurrence (without the Executive&rsquo;s prior written consent), of any of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
material reduction in the Executive&rsquo;s authority, duties, or responsibilities or a material reduction in the authority, duties or
responsibilities of the person to whom the Executive reports;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>the
relocation of the principal place at which the Executive provides services to the Company by at least fifty (50) miles and to a location
such that the Executive&rsquo;s daily commuting distance is increased; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
material reduction of the Executive&rsquo;s Base Salary, except for across-the-board salary reductions based on the Company&rsquo;s financial
performance similarly affecting all or substantially all senior management employees of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>a
material breach by the Company of its obligations under this letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No termination will be treated
as a termination by the Executive for Good Reason unless (x)&nbsp;the Executive has given written notice to the Company of the Executive&rsquo;s
intention to terminate the Executive&rsquo;s employment for Good Reason, describing the grounds for such action, no later than ninety
(90) days after the first occurrence of such circumstances, (y)&nbsp;the Executive has provided the Company with at least thirty (30)
days in which to cure the circumstances, and (z)&nbsp;if the Company is not successful in curing the circumstances, the Executive ends
the Executive&rsquo;s employment within thirty (30) calendar days following the cure period in (y).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">8. <I>Effect of Termination</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;<I>All Terminations
Other Than by the Company Without Cause or by the Executive With Good Reason</I>. If the Executive&rsquo;s employment is terminated under
any circumstances other than a termination by the Company without Cause or a termination by the Executive with Good Reason (including
a voluntary termination by the Executive without Good Reason or a termination by the Company for Cause or due to the Executive&rsquo;s
death or Disability), the Company&rsquo;s obligations under this Agreement shall immediately cease and the Executive shall only be entitled
to receive (i)&nbsp;the Base Salary that has accrued and to which the Executive is entitled as of the effective date of such termination,
to be paid in accordance with the Company&rsquo;s established payroll procedure and applicable law but no later than the next regularly
scheduled pay period, (ii)&nbsp;unreimbursed business expenses for which expenses the Executive has timely submitted appropriate documentation
in accordance with Section&nbsp;5 hereof, (iii)&nbsp;any amounts or benefits to which the Executive is then entitled under the terms of
the benefit plans then-sponsored by the Company in accordance with their terms (and not accelerated to the extent acceleration does not
satisfy Section&nbsp;409A of the Internal Revenue Code of 1986, as amended, (the &ldquo;Code&rdquo;)), and (iv)&nbsp;any accrued but unused
vacation time through the date of termination, to be paid in accordance with Company policy and applicable law (the payments described
in this sentence, the &ldquo;Accrued Obligations&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;<I>Termination by
the Company Without Cause or by the Executive With Good Reason More Than Three Months Prior to or More Than Twelve Months Following a
Change in Control</I>. If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason
more than three (3)&nbsp;months prior to, or more than twelve (12) months following, a Change in Control (as defined below), the Executive
shall be entitled to the Accrued Obligations. In addition, and subject to <U>Exhibit&nbsp;A</U> and the conditions of Section&nbsp;8(d),
the Company shall: (i)&nbsp;continue to pay to the Executive, in accordance with the Company&rsquo;s regularly established payroll procedures,
the Executive&rsquo;s Base Salary for a period of twelve (12) months; (ii)&nbsp;pay to the Executive, in a single lump sum on the Payment
Date (as defined below) an amount equal to one hundred percent (100%) of the Executive&rsquo;s
Target Bonus for the year in which termination occurs, prorated based on a fraction, the numerator of which is the number of days during
the calendar year in which the Executive&rsquo;s termination date occurs that the Executive remained employed by the Company and the denominator
of which is 365 (such amount, the &ldquo;Pro Rata Bonus&rdquo;); and (iii)&nbsp;provided the Executive is eligible for and timely elects
to continue receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for twelve (12) months following
the Executive&rsquo;s termination date or until the Executive becomes eligible for coverage under another employer&rsquo;s group health
plan or is no longer eligible for coverage under COBRA, whichever occurs first, the share of the premium for health coverage that is paid
by the Company for active and similarly-situated employees who receive the same type of coverage, unless the Company&rsquo;s provision
of such COBRA payments will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply (collectively,
the &ldquo;Severance Benefits&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;<I>Termination by
the Company Without Cause or by the Executive With Good Reason Within Three Months Prior to or Twelve Months Following a Change in Control</I>.
If the Executive&rsquo;s employment is terminated by the Company without Cause or by the Executive with Good Reason within the period
that begins three (3)&nbsp;months prior to and ends twelve (12) months following a Change in Control, then the Executive shall be entitled
to the Accrued Obligations. In addition, and subject to <U>Exhibit&nbsp;A</U> and the conditions of Section&nbsp;8(d), the Company shall:
(i)&nbsp;pay to the Executive, in a single lump sum on the Payment Date, an amount equal to the sum of (x)&nbsp;eighteen (18) months of
the Executive&rsquo;s Base Salary, and (y)&nbsp;one hundred fifty percent (150%) of the Executive&rsquo;s Target Bonus for the year in
which termination occurs or, if higher, the Executive&rsquo;s Target Bonus immediately prior to the Change in Control, (ii)&nbsp;pay to
the Executive, in a single lump sum on the Payment Date, the Pro Rata Bonus which Pro Rata Bonus, shall, for the avoidance of doubt, be
determined by reference to the Executive&rsquo;s Target Bonus for the year in which termination occurs, or, if higher, the Executive&rsquo;s
Target Bonus immediately prior to the Change in Control, (iii)&nbsp;provided the Executive is eligible for and timely elects to continue
receiving group medical insurance pursuant to the &ldquo;COBRA&rdquo; law, continue to pay for eighteen (18) months following the Executive&rsquo;s
termination date or until the Executive becomes eligible for coverage under another employer&rsquo;s group health plan or is no longer
eligible for coverage under COBRA, whichever occurs first, the share of the premium for health coverage that is paid by the Company for
active and similarly-situated employees who receive the same type of coverage, unless the Company&rsquo;s provision of such COBRA payments
will violate the nondiscrimination requirements of applicable law, in which case this benefit will not apply, and (iv)&nbsp;provide that
the vesting of the Executive&rsquo;s then-unvested equity awards that vest based solely on the passage of time shall be accelerated, such
that all such then-unvested time-based equity awards shall vest and become fully exercisable or non-forfeitable as of the later of the
date of the Change in Control and the Executive&rsquo;s termination date (collectively, the &ldquo;Change in Control Severance Benefits&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;<I>Release</I>. As
a condition of the Executive&rsquo;s receipt of the Severance Benefits or the Change in Control Severance Benefits, as applicable, the
Executive must execute and deliver to the Company a separation and release of claims agreement in substantially the form attached hereto
as <U>Exhibit&nbsp;B</U> (the &ldquo;Release&rdquo;), which Release must become irrevocable within sixty (60) days following the date
of the Executive&rsquo;s termination of employment (or such shorter period as may be directed by the Company). The Severance Benefits
or the Change in Control Severance Benefits, as applicable, will be paid or commence to be paid in the first regular payroll beginning
after the Release becomes effective, provided that if the foregoing sixty (60) day period would end in a calendar year subsequent to the year in which
the Executive&rsquo;s employment ends, the Severance Benefits or Change in Control Severance Benefits, as applicable, will not be paid
or begin to be paid before the first payroll of the subsequent calendar year (the date the Severance Benefits or Change in Control Severance
Benefits, as applicable, are paid or commence pursuant to this sentence, the &ldquo;Payment Date&rdquo;). The Executive must continue
to comply with all post-employment obligations under law or in any agreement between the Executive and the Company, including the Restrictive
Covenant Agreements, any similar agreement with the Company and as set forth in the Release in order to be eligible to receive or continue
receiving the Severance Benefits or Change in Control Severance Benefits, as applicable. For the avoidance of doubt, if the Executive&rsquo;s
employment is terminated by the Company without Cause or by the Executive with Good Reason prior to a Change in Control, (i)&nbsp;any
then-outstanding and unvested time-based equity awards held by the Executive shall remain outstanding (but any vesting shall be suspended)
for up to (but no longer than) three (3)&nbsp;months following the date of termination so that, if it is later determined that such termination
occurred during the three (3)-month period prior to the closing of a Change in Control and the Executive is entitled to Change in Control
acceleration and/or Change in Control Severance Benefits rather than Severance Benefits, the vesting of such awards may be accelerated,
in accordance with Section&nbsp;8(c), immediately prior to the closing of the Change in Control and (ii)&nbsp;any Change in Control Severance
Benefits shall be reduced by any Severance Benefits previously paid to the Executive, if it is later determined that the termination occurred
during the three (3)- month period prior to the closing of a Change in Control and that the Executive is entitled to Change in Control
Severance Benefits rather than Severance Benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&nbsp;<I>Change in Control
Definition</I>. For purposes of this Agreement, &ldquo;Change in Control&rdquo; shall mean the occurrence of any of the following events,
provided that such event or occurrence constitutes a change in the ownership or effective control of the Company, or a change in the ownership
of a substantial portion of the assets of the Company, as defined in Treasury Regulation &sect;&sect; 1.409A-3(i)(5)(v), (vi)&nbsp;and
(vii): (i)&nbsp;the acquisition by an individual, entity or group (within the meaning of Section&nbsp;13(d)(3)&nbsp;or 14(d)(2)&nbsp;of
the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;)) (a &ldquo;Person&rdquo;) of beneficial ownership of any capital
stock of the Company if, after such acquisition, such Person beneficially owns (within the meaning of Rule&nbsp;13d-3 under the Exchange
Act) fifty percent (50%) or more of either (x)&nbsp;the then-outstanding shares of common stock of the Company (the &ldquo;Outstanding
Company Common Stock&rdquo;) or (y)&nbsp;the combined voting power of the then-outstanding securities of the Company entitled to vote
generally in the election of directors (the &ldquo;Outstanding Company Voting Securities&rdquo;); provided, however, that for purposes
of this subsection (i), the following acquisitions shall not constitute a Change in Control: (1)&nbsp;any acquisition directly from the
Company or (2)&nbsp;any acquisition by any entity pursuant to a Business Combination (as defined below) which complies with clauses (x)&nbsp;and
(y)&nbsp;of subsection (iii)&nbsp;of this definition; or (ii)&nbsp;a change in the composition of the Board that results in the Continuing
Directors (as defined below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of a successor
corporation to the Company), where the term &ldquo;Continuing Director&rdquo; means at any date a member of the Board (x)&nbsp;who was
a member of the Board on the Effective Date or (y)&nbsp;who was nominated or elected subsequent to such date by at least a majority of
the directors who were Continuing Directors at the time of such nomination or election or whose election to the Board was recommended
or endorsed by at least a majority of the directors who were Continuing Directors at the time of such nomination or election; provided,
however, that there shall be excluded from this clause (y)&nbsp;any individual whose initial assumption of office occurred as a result
of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened
solicitation of proxies or consents, by or on behalf of a person other than the Board; or (iii)&nbsp;the consummation of a merger, consolidation,
reorganization, recapitalization or share exchange involving the Company, or a sale or other disposition of all or substantially all of
the assets of the Company (a &ldquo;Business Combination&rdquo;), unless, immediately following such Business Combination, each of the
following two (2)&nbsp;conditions is satisfied: (x)&nbsp;all or substantially all of the individuals and entities who were the beneficial
owners of the Outstanding Company Common Stock and Outstanding Company Voting Securities immediately prior to such Business Combination
beneficially own, directly or indirectly, more than fifty percent (50%) of the then-outstanding shares of common stock and the combined
voting power of the then-outstanding securities entitled to vote generally in the election of directors, respectively, of the resulting
or acquiring corporation in such Business Combination (which shall include, without limitation, a corporation which as a result of such
transaction owns the Company or substantially all of the Company&rsquo;s assets either directly or through one (1)&nbsp;or more subsidiaries)
(such resulting or acquiring corporation is referred to herein as the &ldquo;Acquiring Corporation&rdquo;) in substantially the same proportions
as their ownership of the Outstanding Company Common Stock and Outstanding Company Voting Securities, respectively, immediately prior
to such Business Combination and (y)&nbsp;no Person (excluding any employee benefit plan (or related trust) maintained or sponsored by
the Company or by the Acquiring Corporation) beneficially owns, directly or indirectly, fifty percent (50%) or more of the then-outstanding
shares of common stock of the Acquiring Corporation, or of the combined voting power of the then-outstanding securities of such corporation
entitled to vote generally in the election of directors (except to the extent that such ownership existed prior to the Business Combination);
or (iv)&nbsp;the liquidation or dissolution of the Company. The foregoing notwithstanding, the Executive acknowledges and agrees that
the Merger shall not constitute a Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&nbsp;<I>Resignation from
other Positions</I>. If, as of the date that the Executive&rsquo;s employment terminates for any reason, the Executive is a member of
the Board (or the board of directors of any entity affiliated with the Company), or hold any other offices or positions with the Company
(or any entity affiliated with the Company), the Executive shall, unless otherwise requested by the Company, immediately relinquish and/or
resign from any such board memberships, offices and positions as of the date the Executive&rsquo;s employment terminates. The Executive
agrees to execute such documents and take such other actions as the Company may request to reflect such relinquishments and/or resignation(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9. <I>Absence of Restrictions</I>. The Executive
represents and warrants that the Executive is not bound by any employment contracts, restrictive covenants or other restrictions that
prevent (or purports to prevent) the Executive from carrying out the Executive&rsquo;s responsibilities for the Company, or which are
in any way inconsistent with any of the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10. <I>Notice</I>. Any notice delivered under
this Agreement shall be deemed duly delivered three (3)&nbsp;business days after it is sent by registered or certified mail, return receipt
requested, postage prepaid, one (1)&nbsp;business day after it is sent for next-business day delivery via a reputable nationwide overnight
courier service, or immediately upon hand delivery, in each case to the address of the recipient set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">At the address set forth in the Executive&rsquo;s
personnel file</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">To Company, following the Effective
Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">OrthoCellix,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">11 Great Valley Parkway</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Malvern PA 19355</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Attn: Michael Shine</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20">Either Party may change the address
to which notices are to be delivered by giving notice of such change to the other Party in the manner set forth in this Section&nbsp;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11. <I>Applicable Law and Forum</I>. This Agreement
shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania (without reference to the conflict
of laws provisions thereof). Any action, suit or other legal proceeding arising under or relating to any provision of this Agreement shall
be commenced only in a court of the Commonwealth of Pennsylvania (or, if appropriate, a federal court located within the Commonwealth
of Pennsylvania), and the Company and the Executive each consent to the exclusive jurisdiction of such a court. The Company and the Executive
each hereby irrevocably waives any right to a trial by jury in any action, suit or other legal proceeding arising under or relating to
any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12. <I>Successors and Assigns</I>. This Agreement
shall be binding upon and inure to the benefit of both Parties and their respective successors and assigns, including any corporation
with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that the obligations
of the Executive are personal and shall not be assigned by the Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">13. <I>At-Will Employment</I>. This Agreement
shall not be construed as an agreement, either expressed or implied, to employ the Executive for any stated term, and shall in no way
alter the Company&rsquo;s policy of employment at will, under which both the Executive and the Company remain free to terminate the employment
relationship, with or without cause, at any time, with or without notice. Although the Executive&rsquo;s job duties, title, compensation
and benefits, as well as the Company&rsquo;s personnel policies and procedures, may change from time to time, the &ldquo;at-will&rdquo;
nature of the Executive&rsquo;s employment may only be changed by a written agreement signed by the Executive and a duly authorized representative
of the Company, which written agreement expressly states the intention to modify the at-will nature of the Executive&rsquo;s employment,
provided, however, that nothing in the foregoing shall alter any rights the Executive may have as set forth in Section&nbsp;8 above. Similarly,
nothing in this Agreement shall be construed as an agreement, either express or implied, to pay the Executive any compensation or grant
the Executive any benefit beyond the end of the Executive&rsquo;s employment with the Company, except as explicitly set forth in Section&nbsp;8
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">14. <I>Acknowledgment</I>. The Executive states
and represents that the Executive has had an opportunity to fully discuss and review the terms of this Agreement with an attorney. The
Executive further states and represents that the Executive has carefully read this Agreement, understands the contents herein, freely
and voluntarily assents to all of the terms and conditions hereof, and signs the Executive&rsquo;s name of the Executive&rsquo;s own free
act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15. <I>No Oral Modification, Waiver, Cancellation
or Discharge</I>. This Agreement may be amended or modified only by a written instrument executed by both the Company and the Executive.
No delay or omission by the Company in exercising any right under this Agreement shall operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a
bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16. <I>Captions and Pronouns</I>. The captions
of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of
any section of this Agreement. Whenever the context may require, any pronouns used in this Agreement shall include the corresponding masculine,
feminine or neuter forms, and the singular forms of nouns and pronouns shall include the plural, and vice versa.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17. <I>Interpretation</I>. The Parties agree that
this Agreement will be construed without regard to any presumption or rule&nbsp;requiring construction or interpretation against the drafting
Party. References in this Agreement to &ldquo;include&rdquo; or &ldquo;including&rdquo; should be read as though they said &ldquo;without
limitation&rdquo; or equivalent forms. Except where the context requires otherwise, references in this Agreement to the &ldquo;Board&rdquo;
shall include any authorized committee thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">18. <I>Severability</I>. Each provision of this
Agreement must be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement
is held to be prohibited by or invalid under applicable law, such provision will be ineffective only to the extent of such prohibition
or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Agreement. Moreover, if a court
of competent jurisdiction determines any of the provisions contained in this Agreement to be unenforceable because the provision is excessively
broad in scope, whether as to duration, activity, geographic application, subject or otherwise, it will be construed, by limiting or reducing
it to the extent legally permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the intent of
the Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">19. <I>Modified Section&nbsp;280G Cutback</I>.
Notwithstanding any other provision of this Agreement, except as set forth in Section&nbsp;19(b), in the event that the Company undergoes
a &ldquo;Change in Ownership or Control&rdquo; (as defined below), the following provisions shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&nbsp;The Company shall
not be obligated to provide to the Executive any portion of any &ldquo;Contingent Compensation Payments&rdquo; (as defined below) that
the Executive would otherwise be entitled to receive to the extent necessary to eliminate any &ldquo;excess parachute payments&rdquo;
(as defined in Section&nbsp;280G(b)(1)&nbsp;of the Code) for the Executive. For purposes of this Section&nbsp;19, the Contingent Compensation
Payments so eliminated shall be referred to as the &ldquo;Eliminated Payments&rdquo; and the aggregate amount (determined in accordance
with Treasury Regulation Section&nbsp;1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated
shall be referred to as the &ldquo;Eliminated Amount.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&nbsp;Notwithstanding
the provisions of Section&nbsp;19(a), no such reduction in Contingent Compensation Payments shall be made if (1)&nbsp;the Eliminated
Amount (computed without regard to this sentence) exceeds (2)&nbsp;one hundred percent (100%) of the aggregate present value (determined
in accordance with Treasury Regulation Section&nbsp;1.280G-1, Q/A-31 and Q/A-32 or any successor provisions) of the amount of any additional
taxes that would be incurred by the Executive if the&#8239;Eliminated Payments (determined without regard to this sentence) were paid to the
Executive (including state and federal income taxes on the Eliminated Payments, the excise tax imposed by Section&nbsp;4999 of the Code
payable with respect to all of the Contingent Compensation Payments in excess of the Executive&rsquo;s &ldquo;base amount&rdquo; (as
defined in Section&nbsp;280G(b)(3)&nbsp;of the Code), and any withholding taxes). The override of such reduction in Contingent Compensation
Payments pursuant to this Section&nbsp;19(b)&nbsp;shall be referred to as a &ldquo;Section&nbsp;19(b)&nbsp;Override.&rdquo; For purpose
of this paragraph, if any federal or state income taxes would be attributable to the receipt of any Eliminated Payment, the amount of
such taxes shall be computed by multiplying the amount of the Eliminated Payment by the maximum combined federal and state income tax
rate provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&nbsp;For purposes of this
Section&nbsp;19 the following terms shall have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;Change
in Ownership or Control&rdquo; shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial
portion of the assets of the Company determined in accordance with Section&nbsp;280G(b)(2)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>&ldquo;Contingent
Compensation Payment&rdquo; shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this
Agreement or otherwise) to or for the benefit of a &ldquo;disqualified individual&rdquo; (as defined in Section&nbsp;280G(c)&nbsp;of the
Code) and that is contingent (within the meaning of Section&nbsp;280G(b)(2)(A)(i)&nbsp;of the Code) on a Change in Ownership or Control
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&nbsp;Any payments or
other benefits otherwise due to the Executive following a Change in Ownership or Control that could reasonably be characterized (as determined
by the Company) as Contingent Compensation Payments (the &ldquo;Potential Payments&rdquo;) shall not be made until the dates provided
for in this Section&nbsp;19(d). Within thirty (30) days after each date on which the Executive first becomes entitled to receive (whether
or not then due) a Contingent Compensation Payment relating to such Change in Ownership or Control, the Company shall determine and notify
the Executive (with reasonable detail regarding the basis for its determinations) (1)&nbsp;which Potential Payments constitute Contingent
Compensation Payments, (2)&nbsp;the Eliminated Amount and (3)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override is applicable. Within
thirty (30) days after delivery of such notice to the Executive, the Executive shall deliver a response to the Company (the &ldquo;Executive
Response&rdquo;) stating either (A)&nbsp;that the Executive agrees with the Company&rsquo;s determination pursuant to the preceding sentence
or (B)&nbsp;that the Executive disagrees with such determination, in which case the Executive shall set forth (x)&nbsp;which Potential
Payments should be characterized as Contingent Compensation Payments, (y)&nbsp;the Eliminated Amount, and (z)&nbsp;whether the Section&nbsp;19(b)&nbsp;Override
is applicable. In the event that the Executive fails to deliver an Executive Response on or before the required date, the Company&rsquo;s
initial determination shall be final. If and to the extent that any Contingent Compensation Payments are required to be treated as Eliminated
Payments pursuant to this Section&nbsp;19, then the payments shall be reduced or eliminated, as determined by the Company, in the following
order: (i)&nbsp;any cash payments, (ii)&nbsp;any taxable benefits, (iii)&nbsp;any nontaxable benefits, and (iv)&nbsp;any vesting of equity
awards in each case in reverse order beginning with payments or benefits that are to be paid the farthest in time from the date that
triggers the applicability of the excise tax, to the extent necessary to maximize the Eliminated Payments. If the Executive states in
the Executive Response that the Executive agrees with the&#8239;Company&rsquo;s determination, the Company shall make the Potential Payments
to the Executive within three (3)&nbsp;business days following delivery to the Company of the Executive Response (except for any Potential
Payments which are not due to be made until after such date, which Potential Payments shall be made on the date on which they are due).
If the Executive states in the Executive Response that the Executive disagrees with the Company&rsquo;s determination, then, for a period
of sixty (60) days following delivery of the Executive Response, the Executive and the Company shall use good faith efforts to resolve
such dispute. If such dispute is not resolved within such 60-day period, such dispute shall be settled exclusively by arbitration as
provided in Section&nbsp;11 of this Agreement. The Company shall, within three (3)&nbsp;business days following delivery to the Company
of the Executive Response, make to the Executive those Potential Payments as to which there is no dispute between the Company and the
Executive regarding whether they should be made (except for any such Potential Payments which are not due to be made until after such
date, which Potential Payments shall be made on the date on which they are due). The balance of the Potential Payments shall be made
within three (3)&nbsp;business days following the resolution of such dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provisions of this Section&nbsp;19
are intended to apply to any and all payments or benefits available to the Executive under this Agreement or any other agreement or plan
under which the Executive may receive Contingent Compensation Payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">20. <I>Entire Agreement</I>. Except as expressly
provided in the Merger Agreement, any other agreements to which the Executive is or will be party in connection with the Merger and Section&nbsp;1
hereof, this Agreement constitutes the entire agreement between the Parties and supersedes and replaces all prior agreements and understandings,
whether written or oral, relating to the subject matter of this Agreement, including, without limitation, the Prior Agreement; provided,
however, and for the avoidance of doubt, nothing herein shall be deemed to supersede the Restrictive Covenant Agreements, which remain
in full force and effect as set forth in Section&nbsp;6 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20">IN WITNESS WHEREOF, the Parties
hereto have executed this Agreement as of the day and year set forth above.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 42%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carisma Therapeutics,&nbsp;Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sanford Zweifach</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanford Zweifach</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair of the Board of Directors</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="padding-left: 0.25in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">EXECUTIVE:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven Kelly</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #231f20">Steven Kelly</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20">Service as a non-employee member
on the board of directors of Artelo Biosciences,&nbsp;Inc. in a non-operating capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B><U>EXHIBIT&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Payments Subject to Section&nbsp;409A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to this <U>Exhibit&nbsp;A</U>, any severance payments or benefits that may be due under the Agreement shall begin only upon the date of
the Executive&rsquo;s &ldquo;separation from service&rdquo; (determined as set forth below) which occurs on or after the termination of
the Executive&rsquo;s employment. The following rules&nbsp;shall apply with respect to distribution of the severance payments or benefits,
if any, to be provided to the Executive under the Agreement, as applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>It
is intended that each installment of the severance payments or benefits provided under the Agreement shall be treated as a separate &ldquo;payment&rdquo;
for purposes of Section&nbsp;409A of the Internal Revenue Code (&ldquo;Section&nbsp;409A&rdquo;). Neither the Company nor the Executive
shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted
or required by Section&nbsp;409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is not a &ldquo;specified
employee&rdquo; (within the meaning of Section&nbsp;409A), then each installment of the severance payments or benefits shall be made on
the dates and terms set forth in the letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If,
as of the date of the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company, the Executive is a &ldquo;specified employee&rdquo;
(within the meaning of Section&nbsp;409A), then:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Each installment of the severance payments or benefits due under the Agreement that, in accordance with
the dates and terms set forth herein, will in all circumstances, regardless of when the Executive&rsquo;s separation from service occurs,
be paid within the short-term deferral period (as defined under Section&nbsp;409A) shall be treated as a short-term deferral within the
meaning of Treasury Regulation Section&nbsp;1.409A-1(b)(4)&nbsp;to the maximum extent permissible under Section&nbsp;409A and shall be
paid on the dates and terms set forth in the Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">Each installment of the severance payments or benefits due under the Agreement that is not described in
this <U>Exhibit&nbsp;A</U>, Section&nbsp;1(c)(i)&nbsp;and that would, absent this subsection, be paid within the six (6)-month period
following the Executive&rsquo;s &ldquo;separation from service&rdquo; from the Company shall not be paid until the date that is six (6)&nbsp;months
and one day after such separation from service (or, if earlier, the Executive&rsquo;s death), with any such installments that are required
to be delayed being accumulated during the six (6)-month period and paid in a lump sum on the date that is six months and one day following
the Executive&rsquo;s separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms
set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of payments or
benefits if and to the maximum extent that that such installment is deemed to be paid&#8239;under a separation pay plan that does
not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii)&nbsp;(relating to separation
pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section&nbsp;1.409A-1(b)(9)(iii)&nbsp;must
be paid no later than the last day of the Executive&rsquo;s second taxable year following the taxable year in which the separation from
service occurs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
determination of whether and when the Executive&rsquo;s separation from service from the Company has occurred shall be made and in a manner
consistent with, and based on the presumptions set forth in, Treasury Regulation Section&nbsp;1.409A-1(h). Solely for purposes of Section&nbsp;2
of this <U>Exhibit&nbsp;A</U>, &ldquo;Company&rdquo; shall include all persons with whom the Company would be considered a single employer
under Section&nbsp;414(b)&nbsp;and 414(c)&nbsp;of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All
reimbursements and in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section&nbsp;409A
to the extent that such reimbursements or in-kind benefits are subject to Section&nbsp;409A, including, where applicable, the requirements
that (i)&nbsp;any reimbursement is for expenses incurred during the Executive&rsquo;s lifetime (or during a shorter period of time specified
in the Agreement), (ii)&nbsp;the amount of expenses eligible for reimbursement during a calendar year may not affect the expenses eligible
for reimbursement in any other calendar year, (iii)&nbsp;the reimbursement of an eligible expense will be made on or before the last day
of the calendar year following the year in which the expense is incurred and (iv)&nbsp;the right to reimbursement is not subject to set
off or liquidation or exchange for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company makes no representation or warranty and shall have no liability to the Executive or to any other person if any of the provisions
of the Agreement (including this <U>Exhibit&nbsp;A</U>) are determined to constitute deferred compensation subject to Section&nbsp;409A
but that do not satisfy an exemption from, or the conditions of, that section.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT><FONT STYLE="font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Agreement is intended to comply with, or be exempt from, Section&nbsp;409A and shall be interpreted accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20">[Remainder of page&nbsp;intentionally
left blank.]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>EXHIBIT&nbsp;B<SUP>1</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>Sample Separation and Release
Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[Insert Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20"><B>[Insert Name]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20">Dear <B>[Insert Name]</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the termination
of your employment with OrthoCellix,&nbsp;Inc.(formerly named Carisma Therapeutics Inc.) (the &ldquo;Company&rdquo;) on <B>[Separation
Date]</B>, you are eligible to receive [Severance Benefits] [Change in Control Severance Benefits] as described in Section&nbsp;8 of the
employment agreement executed between you and the Company dated <U>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>
(the &ldquo;Employment Agreement&rdquo;) if you sign and return this letter agreement to me by <B>[Return Date &ndash; [7]/[21]/[45] days
from date of receipt of this letter agreement] [and it becomes binding between you and the Company</B>]. By signing and returning this
letter agreement [<B>and not revoking your acceptance]</B>, you will be agreeing to the terms and conditions set forth in the numbered
paragraphs below, including the release of claims set forth in paragraph 2. Therefore, you are advised to consult with an attorney before
signing this letter agreement and you have been given at least [<B>seven/twenty-one (21)/forty-five (45)]<SUP>2</SUP></B> days to do so.
[<B>If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7)&nbsp;day period after you
have signed it (the &ldquo;Revocation Period&rdquo;) by notifying me in writing. If you do not so revoke, this letter agreement will become
a binding agreement between you and the Company upon the expiration of the Revocation Period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although your receipt of the
[Severance Benefits] [Change in Control Severance Benefits] is expressly conditioned on your entering into this letter agreement, the
following will apply regardless of whether or not you do so:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #231f20">As of the Separation Date, all salary payments from the Company will cease
and any benefits you had as of the Separation Date under Company-provided benefit plans, programs, or practices will terminate, except
as required by federal or state law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #231f20">You will receive payment for your final wages and any unused vacation time
accrued through the Separation Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #231f20">You may, if eligible and at your own cost, elect to continue receiving group
medical insurance pursuant to applicable &ldquo;COBRA&rdquo; law. Please consult the COBRA materials to be provided under separate cover
for details regarding these benefits.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Note: The Company may revise this release agreement in its sole discretion to reflect changes in law, additional statutes or claims, benefits,
or employee&rsquo;s circumstances, so that the Company receives the benefit of the most complete release of claims that is legally permissible
(without releasing employee&rsquo;s right to receive the Severance Benefits), and the Company may also change the timing, if required
to obtain such release. This footnote and the other footnotes herein are part of the form of release and are to be removed only when the
Company finalizes the letter agreement for execution.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
Consideration period depends upon circumstances of separation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #231f20">You are obligated to keep confidential and not to use or disclose any and
all non-public information concerning the Company that you acquired during the course of your employment with the Company, including any
non-public information concerning the Company&rsquo;s business affairs, business prospects, and financial condition, except as otherwise
permitted by paragraph 9 below. Further, you remain subject to any and all continuing confidentiality, non-competition and/or non-solicitation
obligations that you may have pursuant to any previous agreement with the Company, including, as may be applicable and without limitation,
the Employment Agreement and the Invention and Non-Disclosure Agreement and Non-Competition and Non-Solicitation Agreement (the &ldquo;Restrictive
Covenant Agreements&rdquo;) referenced therein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="color: #231f20">You must return to the Company no later than the Separation Date all Company
property.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If you elect to timely sign
and return this letter agreement, comply with all of your obligations hereunder, and do not revoke your acceptance in writing within the
Revocation Period, the following numbered paragraphs set forth the terms and conditions that will also apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><B><U>Severance Benefits</U></B> The Company will provide you with the [as may be applicable [Severance
Benefits] or [Change in Control Severance Benefits]] set forth in Section&nbsp;8 of the Employment Agreement (the [&ldquo;Severance Benefits&rdquo;]
[&ldquo;Change in Control Severance Benefits&rdquo;]), <B>s</B>ubject to and in accordance with the terms and conditions thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><B><U>Release</U> &ndash;</B> In consideration of the [Severance Benefits] [Change in Control Severance
Benefits], which you acknowledge you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally
release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their
respective past and present officers, directors, stockholders, partners, members, managers, employees, agents, representatives, plan administrators,
attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the &ldquo;Released Parties&rdquo;)
from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts,
reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions, obligations, liabilities, and expenses
(including attorneys&rsquo; fees and costs), of every kind and nature that you ever had or now have against any or all of the Released
Parties, whether known or unknown, including, but not limited to, any and all claims arising out of or relating to your employment with
and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C.
 &sect; 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. &sect; 12101 et seq., <B>[the Age Discrimination in Employment
Act, 29 U.S.C. &sect; 621 et seq.,] </B>the Genetic Information Nondiscrimination Act of 2008, 42 U.S.C. &sect; 2000ff et seq., the Family
and Medical Leave Act, 29 U.S.C. &sect; 2601 et seq., the Worker Adjustment and Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C.
 &sect; 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. &sect; 701 et seq., Executive Order 11246, Executive Order 11141, the Fair
Credit Reporting Act, 15 U.S.C. &sect; 1681 et seq., and the Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;), 29
U.S.C. &sect; 1001 et seq., all as amended; all claims arising out of the Pennsylvania Human Relations Act, 43 Pa. Stat. &sect; 951 et
seq., the Pennsylvania Equal Pay&#8239;Law, 43 Pa. Stat. &sect; 336.1 et seq.,
the Pennsylvania Wage Payment and Collection Law, 43 Pa. Stat. &sect; 251 et seq., and the Pennsylvania Whistleblower Law, 43 Pa. Stat.
 &sect; 1421 et seq., all as amended; <B>[Insert any other applicable federal, state and local citations at the time of termination;] </B>all
common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation,
fraud, wrongful discharge, and breach of contract (including, without limitation, all claims arising out of or relating to the Employment
Agreement); all claims to any ownership interest in the Company, contractual or otherwise; all state and federal whistleblower claims
to the maximum extent permitted by law; and any claim or damage arising out of your employment with and/or separation from the Company
(including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced
above; provided, however, that nothing in this letter agreement: (i)&nbsp;prevents you from filing a charge with, cooperating with, or
participating in any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment practices
agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such charge, investigation,
or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&rsquo; fees or other remedial relief in connection
with any such charge, investigation or proceeding), (ii)&nbsp;deprives you of any accrued benefits to which you have acquired a vested
right under any employee benefit plan or policy, stock plan or deferred compensation arrangement, any health care continuation to the
extent required by applicable law or any agreement, or any right to severance benefits or any other benefits due to you upon termination
of employment that you may have under the Employment Agreement; or (iii)&nbsp;deprives you of any rights you may have to be indemnified
by the Company as provided in any agreement between the Company and you, or pursuant to the Company&rsquo;s Certificate of Incorporation
or by-laws (recognizing that such indemnification is not guaranteed by this letter agreement and shall be governed by the instrument,
if any, providing for such indemnification).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify"><B><U>Continuing Obligations</U> &ndash;</B> You acknowledge and reaffirm your confidentiality and nondisclosure
obligations discussed above, as well as any and all confidentiality, non-competition, nonsolicitation obligations and/or assignment of
inventions set forth in any previous agreement you may have with the Company (including without limitation the Employment Agreement and
the Restrictive Covenants Agreements referenced therein), which survive your separation from employment with the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><B><U>Non-Disparagement</U> &ndash;</B> You understand and agree that, to the extent permitted by law
and except as otherwise permitted by paragraph 9 below, you will not, in public or private, make any false, disparaging, derogatory or
defamatory statements, online (including, without limitation, on any social media, networking, or employer review site) or otherwise,
to any person or entity, including, but not limited to, any media outlet, industry group, financial institution or current or former employee,
board member, consultant, client or customer of the Company, regarding the Company or any of the other Released Parties, or regarding
the Company&rsquo;s business affairs, business prospects, or financial condition.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify"><B><U>Cooperation</U> &ndash;</B> You agree that, to the extent permitted by law, you shall cooperate
fully with the Company in: (i)&nbsp;any internal investigation; (ii)&nbsp;any investigation, defense or&#8239;prosecution of any claims or actions
which already have been brought, are currently pending, or which may be brought in the future against the Company by a third party or
by or on behalf of the Company against any third party, whether before a state or federal court, any state or federal government agency,
or a mediator or arbitrator; or (iii)&nbsp;any other administrative, regulatory, or judicial inquiry, investigation, proceeding or arbitration.
Your full cooperation hereunder shall include, but not be limited to, making yourself available to the Company upon reasonable notice
for interviews and factual investigations; appearing at the Company&rsquo;s request to give testimony without requiring service of a subpoena
or other legal process; volunteering to the Company pertinent information; and turning over all relevant documents which are in or may
come into your possession. The term &ldquo;cooperation&rdquo; does not mean that you must provide information that is favorable to the
Company; it means only that you will provide truthful information within your knowledge and possession upon request of the Company. The
Company will reimburse you for all reasonable and documented out-of-pocket expenses that you incur at the Company&rsquo;s request to comply
with this paragraph. You further agree that, to the extent permitted by law, you will notify the Company promptly in the event that you
are served with a subpoena (other than a subpoena issued by a government agency), or in the event that you are asked to provide a third
party (other than a government agency) with information concerning any actual or potential complaint or claim against the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify"><B><U>Return of Company Property</U> &ndash;</B> You confirm that you have returned to the Company all
keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software, printers, flash drives
and other storage devices, wireless handheld devices, cellular phones, tablets,&nbsp;etc.), Company identification, and any other Company
owned property in your possession or control, and that you have left intact all, and have otherwise not destroyed, deleted, or made inaccessible
to the Company any, electronic Company documents, including, but not limited to, those that you developed or helped to develop during
your employment, and that you have not (a)&nbsp;retained any copies in any form or media; (b)&nbsp;maintained access to any copies in
any form, media, or location; (c)&nbsp;stored any copies in any physical or electronic locations that are not readily accessible or not
known to the Company or that remain accessible to you; or (d)&nbsp;sent, given, or made accessible any copies to any persons or entities
that the Company has not authorized to receive such electronic or hard copies. You further confirm that you have cancelled all accounts
for your benefit, if any, in the Company&rsquo;s name, including but not limited to, credit cards, telephone charge cards, cellular phone
accounts, and computer accounts.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify"><B><U>Business Expenses and Final Compensation</U> &ndash;</B> You acknowledge that you have been reimbursed
by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements
are owed to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment
by the Company, including payment for all wages, bonuses, and accrued, unused vacation time, and that no other compensation is owed to
you except as provided herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><B><U>Confidentiality</U> &ndash;</B> You understand and agree that, to the extent permitted by law and
except as otherwise permitted by paragraph 9 below, the terms and contents of this letter agreement, and the contents of the negotiations
and discussions resulting in this letter&#8239;agreement, shall be maintained as confidential
by you and your agents and representatives and shall not be disclosed except as otherwise agreed to in writing by the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><B><U>Scope of Disclosure Restrictions</U> &ndash;</B> Nothing contained in this Agreement, any other
agreement with the Company, or any Company policy limits your ability, with or without notice to the Company, to: (i)&nbsp;file a charge
or complaint with any federal, state or local governmental agency or commission (a &ldquo;Government Agency&rdquo;), including without
limitation, the Equal Employment Opportunity Commission, the National Labor Relations Board or the Securities and Exchange Commission
(the &ldquo;SEC&rdquo;); (ii)&nbsp;communicate with any Government Agency or otherwise participate in any investigation or proceeding
that may be conducted by any Government Agency, including by providing non-privileged documents or information; (iii)&nbsp;exercise any
rights under Section&nbsp;7 of the National Labor Relations Act, which are available to non-supervisory employees, including assisting
co-workers with or discussing any employment issue as part of engaging in concerted activities for the purpose of mutual aid or protection;
(iv)&nbsp;discuss or disclose information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct
that you have reason to believe is unlawful; or (v)&nbsp;testify truthfully in a legal proceeding. Any such communications and disclosures
must not violate applicable law and the information disclosed must not have been obtained through a communication that was subject to
the attorney-client privilege (unless disclosure of that information would otherwise be permitted consistent with such privilege or applicable
law). If a Government Agency or any other third party pursues any claim on your behalf, you waive any right to monetary or other individualized
relief (either individually or as part of any collective or class action), but the Company will not limit any right you may have to receive
an award pursuant to the whistleblower provisions of any applicable law or regulation for providing information to the SEC or any other
Government Agency. Further, notwithstanding your confidentiality and nondisclosure obligations, you are hereby advised as follows pursuant
to the Defend Trade Secrets Act: &ldquo;An individual shall not be held criminally or civilly liable under any Federal or State trade
secret law for the disclosure of a trade secret that (A)&nbsp;is made (i)&nbsp;in confidence to a Federal, State, or local government
official, either directly or indirectly, or to an attorney; and (ii)&nbsp;solely for the purpose of reporting or investigating a suspected
violation of law; or (B)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal. An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the
trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A)&nbsp;files
any document containing the trade secret under seal; and (B)&nbsp;does not disclose the trade secret, except pursuant to court order.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify"><B><U>Amendment and Waiver</U> &ndash;</B> This letter agreement shall be binding upon the parties and
may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives
of the parties hereto. This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents,
assigns, heirs, executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter
agreement shall operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion&#8239;shall be effective only in that instance
and shall not be construed as a bar to or waiver of any right on any other occasion.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify"><B><U>Validity</U> &ndash;</B> Should any provision of this letter agreement be declared or be determined
by any court of competent jurisdiction to be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be
affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify"><B><U>Nature of Agreement</U> &ndash; </B>You understand and agree that this letter agreement is a severance
agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify"><B><U>Acknowledgments</U> &ndash; </B>You acknowledge that you have been given at least <B>[seven (7)&nbsp;/
twenty-one (21) / forty-five (45)] </B>days to consider this letter agreement, and that the Company is hereby advising you to consult
with an attorney of your own choosing prior to signing this letter agreement. <B>[You understand that you may revoke this letter agreement
during the Revocation Period by notifying me in writing, and the letter agreement shall not be effective or enforceable until the expiration
of the Revocation Period. You understand and agree that by entering into this letter agreement, you are waiving any and all rights or
claims you might have under the Age Discrimination in Employment Act, as amended by the Older Workers Benefit Protection Act, and that
you have received consideration beyond that to which you were previously entitled.]</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>14.</B></TD><TD STYLE="text-align: justify"><B>[<U>Eligibility for Severance Program</U> &ndash; Attached to this letter agreement as Attachment A
is a description of (i)&nbsp;any class, unit or group of individuals covered by the program of severance benefits which the Company has
offered to you, and any applicable time limits regarding such severance benefit program; and (ii)&nbsp;the job title and ages of all individuals
eligible or selected for such severance benefit program, and the ages of all individuals in the same job classification or organizational
unit who are not eligible or who were not selected for such severance benefit program.]</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify"><B><U>Voluntary Assent</U> &ndash;</B> You affirm that no other promises or agreements of any kind have
been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand
the meaning and intent of this letter agreement. You state and represent that you have had an opportunity to fully discuss and review
the terms of this letter agreement with an attorney. You further state and represent that you have carefully read this letter agreement,
understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own
free act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">16.</TD><TD STYLE="text-align: justify"><B><U>Applicable Law</U> &ndash;</B> This letter agreement shall be interpreted and construed by the laws
of the Commonwealth of Pennsylvania, without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and
recognize the jurisdiction of the courts of the Commonwealth of Pennsylvania, or if appropriate, a federal court located in the Commonwealth
of Pennsylvania (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action
or other proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof. You&#8239;hereby irrevocably waive any right to
a trial by jury in any action, suit or other legal proceeding arising under or relating to any provision of this letter agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify"><B><U>Entire Agreement</U> &ndash;</B> This letter agreement contains and constitutes the entire understanding
and agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and
cancels all previous oral and written negotiations, agreements, and commitments in connection therewith.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">18.</TD><TD STYLE="text-align: justify"><B><U>Tax Acknowledgement</U> &ndash;</B> In connection with the [Severance Benefits] [Change in Control
Severance Benefits], the Company shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall
be responsible for all applicable taxes with respect to such [Severance Benefits] [Change in Control Severance Benefits] under applicable
law. You acknowledge that you are not relying upon the advice or representation of the Company with respect to the tax treatment of the
[Severance Benefits] [Change in Control Severance Benefits].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20">[Signature Page&nbsp;Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20">If you have any questions about
the matters covered in this letter agreement, please call me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Name]</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Title]</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20">I hereby agree to the terms and
conditions set forth above. <B>[I have been given at least [twenty-one (21) / forty-five (45)] days to consider this letter agreement
and I have chosen to execute this on the date below. I intend that this letter agreement will become a binding agreement between me and
the Company if I do not revoke my acceptance during the Revocation Period.]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[Insert Name]</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #231f20">To be returned in a timely manner
as set forth on the first page&nbsp;of this letter agreement, but not to be signed before the close of business on your last day of employment.<SUP>3</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>3</SUP></FONT>
Note: All footnotes will be removed from the final execution version of this agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 24; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tm2524685d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CARISMA THERAPEUTICS INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">August 29, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steven Kelly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[**]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Re: <U>Retention and Transaction Bonus Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Steven:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we discussed, Carisma Therapeutics Inc. (the
 &ldquo;<B><I>Company</I></B>&rdquo;) recognizes and appreciates the contributions you have made to the Company during your employment
and in support of the anticipated merger pursuant to that certain Agreement and Plan of Merger, dated June&nbsp;22, 2025, among the Company,
Azalea Merger Sub,&nbsp;Inc., a Delaware corporation and wholly owned subsidiary of the Company (&ldquo;<B><I>Merger Sub</I></B>&rdquo;),
Ocugen,&nbsp;Inc. (&ldquo;<B><I>Ocugen</I></B>&rdquo;), a Delaware corporation, and OrthoCellix,&nbsp;Inc. (&ldquo;<B><I>OrthoCellix</I></B>&rdquo;),
a Delaware corporation and wholly-owned subsidiary of Ocugen, pursuant to which, Merger Sub will merge with and into OrthoCellix (the
 &ldquo;<B><I>Merger</I></B>&rdquo;). As an incentive for your continued employment with and commitment to the Company,&nbsp;I am pleased
to offer you the following bonuses, subject to the terms and conditions set forth below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please review this Retention and Transaction Bonus
Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) and let me know if you have any questions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD><U>Bonuses</U></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Retention Bonus</U>. If you
remain continuously employed by the Company through the Retention Date (defined below), the Company will pay you a retention bonus in
a lump sum amount equal to the sum of (i)&nbsp;twelve (12) months of your current base salary, and (ii)&nbsp;one hundred percent (100%)
of your 2025 annual discretionary bonus at target, prorated based on the Retention Date (the &ldquo;</FONT><B><I>Retention Bonus</I></B>&rdquo;).
The <B><I>Retention Date</I></B> shall be the date that is the earlier of (y)&nbsp;the date of the closing of the Merger (the &ldquo;<B><I>Closing</I></B>&rdquo;),
and (z)&nbsp;October&nbsp;31, 2025. The Retention Bonus, less applicable taxes and withholdings, will be paid to you on the Payment Date
(as defined in Section&nbsp;2 below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Transaction Bonus</U>. In
addition, if the Closing occurs prior to October&nbsp;31, 2025, contingent upon you remaining continuously employed by the Company through
such Closing, the Company will pay you an additional transaction bonus in a lump sum amount equal to the difference of (i)&nbsp;the sum
of (x)&nbsp;eighteen (18) months of your current base salary, (y)&nbsp;one hundred fifty percent (150%) of your 2025 annual discretionary
bonus at target, and (z)&nbsp;one hundred percent (100%) of your 2025 annual discretionary bonus at target, prorated based on the date
of the Closing, minus (ii)&nbsp;the Retention Bonus (the &ldquo;</FONT><B><I>Transaction Bonus</I></B>&rdquo;). The Transaction Bonus,
less applicable taxes and withholdings, will be paid to you on the Payment Date (as defined in Section&nbsp;2 below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Release of Claims; Payment
Date</U>. As a condition of you receipt of the Retention Bonus, and, if applicable, the Transaction Bonus, you must execute and deliver
to the Company a release of claims agreement in substantially the form attached hereto as <U>Exhibit&nbsp;A</U> (the &ldquo;</FONT><B><I>Release</I></B>&rdquo;)
within seven (7)&nbsp;days following the Retention Date. The Retention Bonus, and, if applicable, the Transaction Bonus,&#8239;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">will
be paid to you in the Company&rsquo;s first regular payroll beginning after you execute the Release (the &ldquo;</FONT><B><I>Payment Date</I></B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Termination of Employment
Prior to the Retention Date</U>. In the event that your employment is terminated for any reason prior to the Retention Date (an &ldquo;</FONT><B><I>Early
Termination</I></B>&rdquo;), you will not be eligible to receive any bonus pursuant to this Agreement. The foregoing notwithstanding,
in the event of an Early Termination, you remain eligible to receive any applicable severance benefits set forth in Section&nbsp;8 of
the Employment Agreement between you and the Company dated March&nbsp;7, 2023 (the &ldquo;<B><I>Employment Agreement</I></B>&rdquo;),
pursuant to the terms and conditions of the Employment Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify"><U>Delayed Closing</U>. In the event that you become eligible for the Retention Bonus on October&nbsp;31,
2025 (<I>i.e</I>., because you remained continually employed by the Company through October&nbsp;31, 2025, and the Closing has not occurred
by that date), as a condition of receiving the Retention Bonus, you agree to forgo the severance benefits set forth in Section&nbsp;8
of the Employment Agreement; provided, however, in lieu of such severance benefits, in the event of a termination by the Company without
Cause (as defined in the Employment Agreement) or by you for Good Reason (as defined in the Employment Agreement), the Company will pay
you a taxable bonus which you may use to cover health insurance costs or for any other purpose in the amount of $3,757 per month (the
 &ldquo;Health Insurance Bonus&rdquo;) until the earlier of (i)&nbsp;a date that is twelve (12) months following your termination date,
and (ii)&nbsp;the date that you become eligible for health insurance benefits through subsequent employment (you agree that should you
become eligible for health insurance benefits through subsequent employment prior to a date that is twelve (12) months following your
termination date, you will so inform the Company in writing within five (5)&nbsp;business days of becoming eligible for such coverage).
As a condition of receiving the Health Insurance Bonus, you must execute and deliver to the Company a separation and release of claims
agreement consistent with the terms and conditions set forth in Section&nbsp;8(d)&nbsp;of the Employment Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Entire Agreement.</U> This
Agreement forms the complete and exclusive statement of terms between you and the Company </FONT>relating to your eligibility to receive
the bonuses set forth herein, and supersedes any other offers, agreements or promises made to you by anyone, whether oral or written,
related to the matters addressed herein.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>At-Will Employment; No Superseding
Effect.</U> This Agreement shall not be construed as an agreement, either express or implied, to employ you for any stated term, and shall
in no way alter the Company&rsquo;s policy of employment at-will, under which both the Company and you remain free to end the employment
relationship for any reason, at any time, with or without cause or notice. This Agreement shall supplement the terms and conditions of
your employment with the Company and shall not supersede any prior written agreements relating </FONT>to the terms of your employment,
including the Employment Agreement, unless explicitly stated herein. In the event any provision of this Agreement is inconsistent with
any provision previously set forth in any other agreement with the Company, such earlier provision shall be deemed superseded only to
the extent necessary to avoid such inconsistency.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Governing Law.</U> This Agreement
shall be governed by the laws of the Commonwealth of Pennsylvania without regard to conflicts of law provisions. </FONT>Any action, suit
or other legal proceeding arising under or relating to any provision of this Agreement shall be commenced only in a court in the Commonwealth
of Pennsylvania (or, if appropriate, a federal court located therein), and you consent to the jurisdiction of such a court.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify"><U>Voluntary Assent</U>. You affirm that no other promises or agreements of any kind have been made to
or with you by any person or entity whatsoever to cause you to sign this Agreement, and that you fully&#8239;understand the meaning and intent of
this Agreement. You further state and represent that you have carefully read this Agreement, understand the contents herein, freely and
voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify"><U>Section&nbsp;409A</U>. Each payment hereunder will be paid within the short-term deferral period (as
defined under Section&nbsp;409A of the Internal Revenue Code of 1986, as amended (&ldquo;Section&nbsp;409A&rdquo;)) and shall be treated
as a short-term deferral within the meaning of Treasury Regulation Section&nbsp;1.409A-1(b)(4)&nbsp;to the maximum extent permissible
under Section&nbsp;409A and shall be paid on the dates and terms set forth in this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Please sign where indicated below to acknowledge
your receipt of this Agreement and your acceptance of all of its terms and conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 47%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Sanford Zweifach</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanford Zweifach</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair of the Board of Directors</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I acknowledge that I have read, understand and
agree to the terms set forth herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven Kelly</FONT></TD>
    <TD STYLE="vertical-align: top; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 40%; border-bottom: Black 1pt solid">August 29, 2025</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Kelly</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #231f20"><B>EXHIBIT&nbsp;A<SUP>1</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Release
of Claims</U></FONT>. In consideration of the Retention Bonus, and, if applicable, the Transaction Bonus, as set forth in the Retention
and Transaction Bonus Agreement to which this release agreement (the &ldquo;<B><I>Release</I></B>&rdquo;) is attached, which you acknowledge
you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge
Carisma Therapeutics Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;), its affiliates, subsidiaries, parent companies, predecessors, and
successors, and all of their respective past and present officers, directors, stockholders, partners, members, managers, employees, agents,
representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively,
the &ldquo;<B><I>Released Parties</I></B>&rdquo;) from any and all claims, charges, complaints, demands, actions, causes of action, suits,
rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages, executions,
obligations, liabilities, and expenses (including attorneys&rsquo; fees and costs), of every kind and nature that you ever had or now
have against any or all of the Released Parties, whether known or unknown, including, but not limited to, any and all claims arising out
of or relating to your employment with the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act
of 1964, 42 U.S.C. &sect; 2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. &sect; 12101 et seq., the Genetic Information
Nondiscrimination Act of 2008, 42 U.S.C. &sect; 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. &sect; 2601 et seq., the Worker
Adjustment and Retraining Notification Act (&ldquo;WARN&rdquo;), 29 U.S.C. &sect; 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C.
 &sect; 701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. &sect; 1681 et seq., and the
Employee Retirement Income Security Act of 1974 (&ldquo;ERISA&rdquo;), 29 U.S.C. &sect; 1001 et seq., all as amended; all claims arising
out of the Pennsylvania Human Relations Act, 43 Pa. Stat. &sect; 951 et seq., the Pennsylvania Equal Pay Law, 43 Pa. Stat. &sect; 336.1
et seq., the Pennsylvania Wage Payment and Collection Law, 43 Pa. Stat. &sect; 251 et seq., and the Pennsylvania Whistleblower Law, 43
Pa. Stat. &sect; 1421 et seq., all as amended; all common law claims including, but not limited to, actions in defamation, intentional
infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation,
all claims arising out of or relating to the Employment Agreement between you and the Company dated March&nbsp;7, 2023, including claims
for severance benefits therein); all claims to any ownership interest in the Company, contractual or otherwise; all state and federal
whistleblower claims to the maximum extent permitted by law; and any claim or damage arising out of your employment with and/or separation
from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not
expressly referenced above; provided, however, that nothing in this letter agreement prevents you from filing a charge with, cooperating
with, or participating in any investigation or proceeding before, the Equal Employment Opportunity Commission or a state fair employment
practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such charge, investigation,
or proceeding, and you further waive any rights or claims to any payment, benefit, attorneys&rsquo; fees or other remedial relief in connection
with any such charge, investigation or proceeding).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Release must be signed and returned to the
Company within seven (7)&nbsp;days following the Retention Date (as defined in the Retention and Transaction Bonus Agreement to which
this Release is attached).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby agree to the terms and conditions set
forth above. I intend that this Release become a binding agreement between me and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
Note: The Company may revise this release agreement in its sole discretion to reflect changes in law, additional statutes or claims, or
other circumstances, so that the Company receives the benefit of the most complete release of claims that is legally permissible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 40%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven Kelly</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agreed to by the Company:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 50%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 10%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 40%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sanford Zweifach</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chair of the Board of Directors</FONT></TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>carm-20250829.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOBebOdzZR+OYkxtmB9bRmqbyck0J8W4C/IPXBWYTwH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:CARM="http://carismatx.com/20250829" elementFormDefault="qualified" targetNamespace="http://carismatx.com/20250829">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://carismatx.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="carm-20250829_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="carm-20250829_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>carm-20250829_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>carm-20250829_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="carm-20250829.xsd#Cover" roleURI="http://carismatx.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://carismatx.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 29,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Carisma Therapeutics Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3675 Market Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite&#160;401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">491-6422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CARM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2524685d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://carismatx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>carm-20250829.xsd</File>
    <File>carm-20250829_lab.xml</File>
    <File>carm-20250829_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2524685d1_8k.htm">tm2524685d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2524685d1_8k.htm": {
   "nsprefix": "CARM",
   "nsuri": "http://carismatx.com/20250829",
   "dts": {
    "schema": {
     "local": [
      "carm-20250829.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "carm-20250829_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "carm-20250829_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2524685d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://carismatx.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-08-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524685d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-08-29",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2524685d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://carismatx.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-25-085705-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-085705-xbrl.zip
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ME+L"P&I+=WVC,(A.MSEJ??D;?>UIR+_<18_2% %>2+#+7 _]-I/F\%_7!(%
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ME0HJQ]BW W;W%4F?EA*OS3\<T%C4:/UD6!'?XBPJ0'7JK)9MG*40?8&.'?J
MC_ 6%6:>#+GG>DZD\P_D$*C!&M!;,$0*=W>47+%@E2%5+^*+M <$I1O%D[#%
M?-^[,[I*/TE?Z^^L)3,3\UHOFI>$-R/GR3=4D;@5QU% 'X0EY@(ZZ.$SJ +8
M%-$B\CH<D6X!*L:M QLY4D@#1=/UA#>=@P$''!,4$C!&\%U^^2O&JH'FXOLV
MZE!,*3&2P(S9%Q!3BA#ZRFR,.J\7)*CI &&MO-PX,,TSB6Z\&_Q:F5>RH1BX
M:IME =+GEC&]?+<F=!,'V)^#;5VEZ5%H(D(M#< $D</#@+SH;(QHY-B,MI[
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M@^?HW*-*1$K2DSI!S(B8C<2YC<-<.>*<HN$H3C.4Z!9R6P8$C=:6H:JY6+A
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MG^$:S'72 ,WN/[O_\W,\*(6?6&T;%KTUE<=#RE^HE;<1\5R5::V0^F%2,6Q
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M(7]A>Y*]'7!D1*JH7K:2%0<2T"B'ET_FS=*FE[VRO):R^_S$%94C;S=?!U=
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M8V:L\X:TA@IGC3UF6@Z#H>S,=(U+JE5=3LL0MP\\!CMVV^[;O>??<BH<UV<
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M\[1AS%P,C.\@HR2_<I/C[W"K?,Q:WG?"0&:;'ZOS,XO"OE15A:>#0Z,_ULI
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M5LT-%;KO +'K-]# ?F-E\4&@1P28!GL<$[,C.0M;-./+)G@B7@V5/7?#6])
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M)U:5:L9)^N1QWXW>&5*N>DBFMIW*Y0QML_(R_ )&= 7:A*-$D!,J8:/8V-I
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MG23_(2'6-.D[9%2B&1 V/&WK*@&!KC+$46))W45K8_R_2Q@VIDO9R7!0M2:
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M-("'TL1),#B09YAU<F+R!FOMT-MDVT-57(+@.<_$4T8"BR*OF4K;"3;V\>B
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M$1 V]<NPBM,-CE)O&++]YBL+V7YS%[*]T[YON?:-W+^8PE,4IP$Y\%[K)2K
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MW#,^A%_@:B63Q1>.1_L28 %OL7;"4YAP[@%'EM>F3Y>\&HH'N.GW>]FP?MJ
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M?E=^,1RX"M/43!4%FM4G51D2"#0,%3S_M#R&NV#0!7$$,.-:PS#91*?B%N,
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M%&?HO8$]&VMR\V(VGB;!RJYKM22CG5H?FPE4QW&,P K#H<%!&X?^(?B1VF4
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MZ1GRA1LB7?)HDUIWWO*:RGTJD(@(9%?)0(@+1 7V&<FLQ-NV9%?.2HD*0-O
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M;K>W^[+I<G>W:UD#V'8"H*XSF!E?G(BK(;YT]Y:W[.5K9RY3_6ZWS@P,(SL
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M\W;W;_5?;=S"/PIY1'\E$O^8Y/\!4$L! A0#%     @ I8(=6^WMBX<L P
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M-C@U9#%?.&LN:'1M4$L! A0#%     @ I8(=6Q9O0A2[7P  X_,! !8
M         ( !A4@  '1M,C4R-#8X-60Q7V5X,3 M,2YH=&U02P$"% ,4
M" "E@AU;@&YF:JT6  !3<@  %@              @ %TJ   =&TR-3(T-C@U
C9#%?97@Q,"TR+FAT;5!+!08     !@ & (T!  !5OP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm2524685d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="carm-20250829.xsd" xlink:type="simple"/>
    <context id="AsOf2025-08-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2025-08-29</startDate>
            <endDate>2025-08-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-08-29" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-08-29" id="Fact000004">0001485003</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-08-29" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-08-29" id="Fact000011">2025-08-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-08-29" id="Fact000012">Carisma Therapeutics Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-08-29" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-08-29" id="Fact000014">001-36296</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-08-29" id="Fact000015">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-08-29" id="Fact000016">3675 Market Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-08-29" id="Fact000017">Suite&#160;401</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-08-29" id="Fact000018">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-08-29" id="Fact000019">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-08-29" id="Fact000020">19104</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-08-29" id="Fact000021">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-08-29" id="Fact000022">491-6422</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-08-29" id="Fact000023">true</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-08-29" id="Fact000024">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-08-29" id="Fact000025">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-08-29" id="Fact000026">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-08-29" id="Fact000027">Common     Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-08-29" id="Fact000028">CARM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-08-29" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-08-29" id="Fact000030">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
